Medicure
Medicure is a pharmaceutical company focused on developing and commercializing therapeutics for the U.S. market, with a portfolio that includes AGGRASTAT and Zypitamag, and a pipeline targeting conditions like PNPO deficiency and Tardive Dyskinesia.
Services
Medicure focuses on the development and commercialization of innovative and affordable therapeutics for the U.S. market. The company aims to become a leading pharmaceutical company in the U.S. and has a growing portfolio of products designed to improve patients' lives. Through its subsidiary Marley Drug, Medicure offers a direct-to-consumer e-commerce pharmacy solution available in all 50 states. The online pharmacy also provides an Extended Supply drug program that serves all 50 states, Washington D.C., and Puerto Rico.
Products
Medicure's product portfolio includes AGGRASTAT (tirofiban HCl) injection and Zypitamag (pitavastatin) tablets. The company is also developing a pipeline of products targeting conditions such as PNPO deficiency and Tardive Dyskinesia. Medicure has received US FDA Fast Track designation for MC-1 for PNPO deficiency, highlighting its commitment to addressing unmet medical needs.
Subsidiaries
Medicure operates several subsidiaries, including Medicure International, Inc. (Barbados), Medicure USA, Inc., and Medicure Pharma, Inc. One of its notable subsidiaries is Marley Drug, an online pharmacy that caters to customers across all 50 states, providing convenient access to medications.
Stock Information
Medicure is publicly traded on the Toronto Stock Exchange Venture under the symbol 'MPH'. This listing allows the company to raise capital and expand its operations, furthering its goal of becoming a leading pharmaceutical company in the U.S. market.